Premier Biomedical (OTCQB:BIEI) CEO talks about their most recent cancer immunotherapy results in their interview with the Uptick Network. He spoke about their presentation at the American Association for Cancer Research (AARC) Confernce. William A. Hartman, President and CEO stated, “This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment.” Learn more about what this could mean for cancer treatment and prevention. https://upticknewswire.com/uptick-network-int...dical-inc/
Uptick Newswire provided the above as a paid service. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence. We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.